Results from the PROMISE-meso study showed better response rates but no survival benefit in pretreated mesothelioma patients treated with pembrolizumab monotherapy compared with chemotherapy. Nonetheless, current results are encouraging and the results of investigations of checkpoint inhibitor treatments in earlier stage mesothelioma are eagerly awaited .
PROMISE-meso randomised 144 patients with advanced pre-treated mesothelioma to either immune checkpoint inhibitor pembrolizumab (200 mg every 3 weeks) or to investigators’ choice of standard chemotherapy (gemcitabine or vinorelbine). Patients in the control group were able to cross over to pembrolizumab at progression. Nearly 4 times more patients responded to immunotherapy. The objective response rate was 22% in patients with pembrolizumab compared with 6% with chemotherapy (P=0.004). Median progression-free survival was 2.5 months (95% CI 2.1 to 4.2) and 3.4 months (95% CI 2.2 to 4.3) respectively (P...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« DNA profiling of carcinoma of unknown primary should inform treatment Next Article
Long-term data from CheckMate 067 »
Table of Contents: ESMO 2019
Solid tumours/pan-tumour data
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.